Chronos Therapeutics Company
Targetting neurological, neurodegenerative disease such as ALS and MS. Chronos is an Oxford-based biotechnology company operating a semi-virtual R&D model to develop a portfolio of therapies in degenerative and behavioral brain diseases. The team utilises a network of industry-leading contract research organisations to develop NCE’s and repurpose existing launched drugs. Chronos also has a dedicated laboratory in Oxford which screens for activity of drugs in brain disease through its proprietary platform, Chronoscreen.
Technology:
AgeTech Companies
Industry:
Healthcare
Headquarters:
United Kingdom
Founded Date:
2009
Employees Number:
11-50
Funding Status:
M&A
Investors Number:
3
Total Funding:
£8M
Estimated Revenue:
$1M to $10M
Last Funding Type:
Venture - Series Unknown
Register and Claim Ownership